Search results
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 6 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its ...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 3 days agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new...
Morningstar· 4 days agoIpsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. “An excellent first-quarter performance has laid ...
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
WKBN 27 Youngstown· 2 days agoCitius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care ...
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse...
ABC 26 New Orleans· 4 days agoPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoStargardt Disease Market to Grow Rapidly at a CAGR of 32% by 2034 | DelveInsight PR Newswire LAS VEGAS, April 24, 2024 The expected launch of potential therapies may increase the Stargardt disease market size in the coming years, assisted by an
Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment...
Morningstar· 3 days agoDALLAS, April 25, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced today the appointment of Allen C. Ho, MD, FACS, FASRS, as Chief Medical
Candel Therapeutics Inc (CADL) Stock: A Value Analysis – News Heater
NewsHeater· 4 days agoThe public float for CADL is 15.66M and currently, short sellers hold a 1.03% of that float. On April 24, 2024, CADL’s average trading volume was 5.28M shares. 3 Tiny Stocks Primed to Explode ...
Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study
Zacks· 5 days agoSanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.
Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse...
StreetInsider· 3 days agoGERMANTOWN, Md., April 24, 2024 /PRNewswire/ --...